GBA's "2021 Stock Phantasma"

The Digital Cell Biology Revolution
A new nanofluidic technology that uses light to manipulate cells is already changing how biotech research is done. Invented by Berkeley Lights and developed with early input from Amgen, the technology has immediate applications and abundant long-term potential.

Welcome to the new frontier of digital cell biology, an emerging technology with immediate uses and abundant long-term potential. The chip and its related devices and software were invented by Berkeley Lights. The first company to embrace the new tool and apply it to biotech R&D was Amgen.

“I would say that it’s already a fairly big deal for us,” said Philip Tagari, Amgen’s VP for Therapeutic Discovery. “We’ve actually put this technology into practice in our antibody discovery work, and it takes about four months off the normal timeline. It’s also our standard method for cell line development, and we’re looking to extend our success in these areas to other applications. It’s starting to feel like a pretty transformative tool.”

In the near- to-medium term, digital cell biology offers scientists a faster and less resource-intensive way to run standard types of biotech experiments. In the long run, it has the potential to do for biology what sequencing did for genetics—make it possible to generate and analyze mountains of data to unravel the complexities of disease.

“I think we’re still very much at the tip of the iceberg in terms of what we can do with the technology and what people will discover by using it,” said Keith Breinlinger, chief technology officer for Berkeley Lights.
 
-Amgen received the first full-scale prototype device in 2013 and the first commercial device, known as the Beacon® platform, in 2016. “Just before we shipped that first Beacon to Amgen in December, the entire company signed it,” Breinlinger recalls. “All our signatures are on it under the hood.

Many benefits of the platform envisioned at the outset have come to fruition. For starters, the chips can miniaturize and integrate experiments that are normally done on several different devices. You can quickly see which cells are making antibodies, if the antibodies bind to their target, and if that binding has the desired impact on the target’s biology. “We are getting the data we need in hours or days, rather than weeks or months,” said Jorgolli.

In addition, the chips eliminate the need to create and grow large numbers of hybridoma cells. In the Beacon’s scaled-down NanoPens™, individual antibody-secreting B cells can thrive long enough to generate useful data. Scientists can then snip out the antibody genes from the best B cells and put them into more durable cells. The top-performers provide the cell line used later to support large-scale clinical testing and manufacturing.

“SO THAT’S WHAT’S HAPPENING!”
The Berkeley Lights technology has become Amgen’s standard platform for cell line development, where it helps researchers to overcome the challenge of keeping cells happy. “Cells don’t like to be by themselves―they like to have friends around,” said Jennitte Stevens, a director in Amgen’s Process Development group. “They send out signals that help each other to grow. Dropping a cell into a 96-well plate is like dropping a person in an ocean. It takes weeks for them to get going again.” Cells prefer the cozier confines of NanoPens and grow better in that environment.
 
Ironwood says linaclotide trial in adults with IBS published 07:52 IRWD Ironwood Pharmaceuticals announced that The American Journal of Gastroenterology - the official journal of The American College of Gastroenterology - published full results from the company's Phase IIIb clinical trial evaluating LINZESS 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation . The results, which can be viewed here, demonstrated that linaclotide 290 mcg administered orally once daily to adult IBS-C patients was associated with a statistically significant and clinically meaningful improvement in overall change in abdominal score compared to placebo.

Not sure what that means how significant?
 
I think I got one...

Anybody who enjoyed the ASANA trade last week which was huge! I think will enjoy this one!

Some of the same characteristics....

June 7)
  • Director of Goedeker (GOED) Ellery Roberts purchased 533,200 shares of company stock at $2.24 per share for a total transaction of $1,194,368
Today)

1847 Goedeker says May revenue up 41.9% to $44.3M 08:08 GOED


BALLWIN, Mo., Jun 16, 2021--(BUSINESS WIRE)--1847 Goedeker Inc. (NYSE American: GOED) ("Goedekers" or the "Company"), the largest pure-play online retailer of household appliances in the US, is pleased to report continued strong growth with record revenue for the month of May 2021, up 41.9% from May 2020 to $44.3 million on May 2021 written orders of $72.6 million.

"We continue to operate at more than a $500 million annual revenue run rate through May. While our fill rate of 61% remains well below our historical 85% rate, we continue to believe we will see a return to normal shipping trends as manufacturers catch production up to consumer demand in the latter part of the third quarter," stated Doug Moore, CEO of Goedekers. "We are now two weeks past the official closing of our Appliances Connection acquisition, and as a combined company, we are executing on a proven direct-to-consumer, or DTC, model of current investment driving scalable growth, and as such, plan to further expand our fulfillment capabilities with the addition of fulfilment centers in key markets, enabling us to further speed up processing times and better serve customers nationally. Current plans are accelerating to open facilities in Texas, California, and Florida, and we anticipate announcing more details regarding the addition of a third facility in the coming weeks."
 
You must log in or register to reply here.
Back
Top